Microdermics closes $1 Million funding to replace hypodermic needles
Microdermics has completed its $1 million financing round, which was oversubscribed and received robust global interest.
List view / Grid view
Microdermics has completed its $1 million financing round, which was oversubscribed and received robust global interest.
Kidney cancer rates have increased by 40% over the last 10 years in the UK, and the rise is expected to continue. An estimated 20,000 kidney cancer cases have been caused by obesity over the last decade in England, according to new figures from Cancer Research UK.
The gene MAFK is known to be induced by the TGF-β signalling pathway, which is involved in breast cancer development. Scientists reported that the MAFK protein, in turn, induced cancerous behaviours in cells by switching on the breast cancer-associated gene GPNMB. MAFK thus represents a link between TGF-β signalling and…
The market of preventive digital health services is estimated to be worth several billion euros in the near future.
Researchers have uncovered molecular details of how pathogenic bacteria fight back against the human immune response to infection.
Over 10 million units of platelets are transfused worldwide each year in one of the most common procedures in clinical medicine. However, platelets derived from human donors can transmit infections and trigger serious immune reactions that eventually render the therapy ineffective (a condition known as alloimmune refractoriness). In addition, since…
The Zika virus, which is spread to people primarily through the bite of an infected Aedes species mosquito, is an impending threat to America’s borders, with over 5000 cases now reported in the continental US. Zika virus infection has been associated with Guillain-Barré Syndrome, and infection during pregnancy has been…
Scientists will develop and test promising new molecules for targeting RAS, one of the most common driving mutations in aggressive, hard to treat cancers including pancreatic and lung cancer.
The successful combination of two therapies results in the growth of specialised vessels that deliver cancer-fighting immune cells to a tumour, potentially leading to more effective treatments and longer survival periods.
Over 90 million blood transfusions are carried out worldwide each year and alternative sources to donor-derived blood are being sought to meet rising demand. In addition there is a need to secure a safer supply of blood products, chiefly in developing countries where there is a relatively higher risk of…
Biochemist and physician Professor Ivan Dikic and microbiologist Professor Volker Müller are very honoured that their pioneering research projects have been selected for this substantial financial support.
New findings could help to extend the lives of patients suffering from one of the most common types of brain tumours - low-grade glioma.
Polyphor Ltd, a clinical stage, privately held Swiss specialty pharma company focused on the development of macrocycle drugs addressing antibiotic resistance and respiratory diseases, has completed a CHF 40 million private placement. Exisiting Polyphor investors contributed to 98% of the financing.
Using state-of-the-art gene editing technology, scientists have discovered a promising target to treat atypical teratoid/rhabdoid tumour (AT/RT) - a highly aggressive and therapy resistant brain tumour that mostly occurs in infants.
Neonatal diabetes mellitus (NDM), or diabetes among infants less than six months of age, is a rare form of diabetes caused by a mutation in genes crusial to the development or function of beta cells. In about half of such cases, the disease becomes permanent (PNDM). Mutations in more than…